B-cell response and antibody production in an inflammatory model of Alzheimers disease

Abstract

Alzheimers disease (AD) diagnoses are on an exponential rise with no current cure or therapeutic options. Amyloid beta is implicated in the pathology of AD through its interaction with neuronal cells and its propagation of a toxic environment in the brain. Metal ions aid in amyloid beta accumulation and their levels become unbalanced in the process. These occurrences lead to a toxic oxidative stress environment which harms neurons and microglial cells, both of which are important for healthy brain function. This interaction is an optimal target for AD therapeutics. Hydroxylpyclen is a compound which can help restore the normal balance of metal ions and reduce oxidative stress. By assessing markers of oxidative stress and cell viability, Hydroxylpyclen can be assessed in vitro in neuron and microglia cells. Results suggests more work needs to be done to find the appropriate dose of the compound to use with these cells, but the methodology is well established for future research to be completed. Successful findings with Hydroxylpyclen could establish it as a potential AD therapeutic.